MedTrace Logo

Psilocybin in Cancer Pain Study

NCT06001749 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-12-16

No results posted yet for this study

Summary

The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer.

The name of the study intervention used in this research study is:

Psilocybin (a tryptamine derivative)

Conditions

Interventions

DRUG

Psilocybin

A tryptamine derivative, capsule, taken orally.

Sponsors & Collaborators

  • Cy Biopharma

    collaborator UNKNOWN

  • Pancreatic Cancer North America

    collaborator UNKNOWN

  • Yvan Beaussant, MD, MSci

    lead OTHER

Principal Investigators

  • Yvan Beaussant, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-23
Primary Completion
2026-07-01
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06001749 on ClinicalTrials.gov